Mycoplasma pneumoniae is one of the significant pathogens causing community-acquired pneumonia in children. Since 2000，macrolide-resistant Mycoplasma pneumoniae（MRMP）has begun to spread in the Western Pacific region，including China. MRMP infection often results in prolonged fever and duration of antibiotic use，increased use of glucocorticoids and second-line antibiotics，and an increased risk of complications and sequelae. In 2024，28 pediatric respiratory experts in our country formulated the “Expert consensus on the diagnosis and treatment of MRMP pneumonia in children”.In this article，we will interpret the hot issues in the consensus to guide pediatricians to grasp the diagnosis and treatment of MRMP pneumonia more accurately.

macrolide-resistant Mycoplasma pneumoniae, expert consensus, diagnosis, treatment

肺炎支原体是儿童社区获得性肺炎的重要病原体之一。2000年以来，大环内酯类耐药肺炎支原体（macrolide-resistant Mycoplasma pneumoniae，MRMP）在西太平洋地区包括我国在内开始流行并迅速蔓延。MRMP 感染往往导致患儿发热及抗生素使用时间延长，使用糖皮质激素及二线抗生素的情况增多，产生并发症、后遗症的风险增加。2024年，国内28位儿科呼吸专家共同制定了《儿童大环内酯类耐药肺炎支原体肺炎诊治专家共识》。该文将就共识中的热点问题展开解读，以指导广大儿科医生更为准确地把握 MRMP 肺炎的诊疗。

大环内酯类耐药肺炎支原体, 专家共识, 诊断, 治疗